These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37436784)

  • 1. CDC: RSV Vaccine Recommended for Older People.
    Harris E
    JAMA; 2023 Aug; 330(5):401. PubMed ID: 37436784
    [No Abstract]   [Full Text] [Related]  

  • 2. The Quest for a Respiratory Syncytial Virus Vaccine for Older Adults: Thinking beyond the F Protein.
    Jenkins VA; Hoet B; Hochrein H; De Moerlooze L
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
    Fleming-Dutra KE; Jones JM; Roper LE; Prill MM; Ortega-Sanchez IR; Moulia DL; Wallace M; Godfrey M; Broder KR; Tepper NK; Brooks O; Sánchez PJ; Kotton CN; Mahon BE; Long SS; McMorrow ML
    MMWR Morb Mortal Wkly Rep; 2023 Oct; 72(41):1115-1122. PubMed ID: 37824423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study.
    Leroux-Roels I; Van Ranst M; Vandermeulen C; Abeele CV; De Schrevel N; Salaun B; Verheust C; David MP; Kotb S; Hulstrøm V
    J Infect Dis; 2024 Feb; 229(2):355-366. PubMed ID: 37699064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Recombinant G Protein Plus Cyclosporine A-Based Respiratory Syncytial Virus Vaccine Elicits Humoral and Regulatory T Cell Responses against Infection without Vaccine-Enhanced Disease.
    Li C; Zhou X; Zhong Y; Li C; Dong A; He Z; Zhang S; Wang B
    J Immunol; 2016 Feb; 196(4):1721-31. PubMed ID: 26792805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults.
    Aliprantis AO; Shaw CA; Griffin P; Farinola N; Railkar RA; Cao X; Liu W; Sachs JR; Swenson CJ; Lee H; Cox KS; Spellman DS; Winstead CJ; Smolenov I; Lai E; Zaks T; Espeseth AS; Panther L
    Hum Vaccin Immunother; 2021 May; 17(5):1248-1261. PubMed ID: 33121346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
    Papi A; Ison MG; Langley JM; Lee DG; Leroux-Roels I; Martinon-Torres F; Schwarz TF; van Zyl-Smit RN; Campora L; Dezutter N; de Schrevel N; Fissette L; David MP; Van der Wielen M; Kostanyan L; Hulstrøm V;
    N Engl J Med; 2023 Feb; 388(7):595-608. PubMed ID: 36791160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults.
    Falsey AR; Williams K; Gymnopoulou E; Bart S; Ervin J; Bastian AR; Menten J; De Paepe E; Vandenberghe S; Chan EKH; Sadoff J; Douoguih M; Callendret B; Comeaux CA; Heijnen E;
    N Engl J Med; 2023 Feb; 388(7):609-620. PubMed ID: 36791161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults.
    Fries L; Shinde V; Stoddard JJ; Thomas DN; Kpamegan E; Lu H; Smith G; Hickman SP; Piedra P; Glenn GM
    Immun Ageing; 2017; 14():8. PubMed ID: 28413427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and Outcomes Among Adults Aged ≥60 Years Hospitalized with Laboratory-Confirmed Respiratory Syncytial Virus - RSV-NET, 12 States, July 2022-June 2023.
    Havers FP; Whitaker M; Melgar M; Chatwani B; Chai SJ; Alden NB; Meek J; Openo KP; Ryan PA; Kim S; Lynfield R; Shaw YP; Barney G; Tesini BL; Sutton M; Talbot HK; Olsen KP; Patton ME;
    MMWR Morb Mortal Wkly Rep; 2023 Oct; 72(40):1075-1082. PubMed ID: 37796742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial.
    Kotb S; Haranaka M; Folschweiller N; Nakanwagi P; Verheust C; De Schrevel N; David MP; Mesaros N; Hulstrøm V
    Respir Investig; 2023 Mar; 61(2):261-269. PubMed ID: 36641341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploratory Analysis of the Economically Justifiable Price of a Hypothetical RSV Vaccine for Older Adults in the Netherlands and the United Kingdom.
    Zeevat F; Luttjeboer J; Paulissen JHJ; van der Schans J; Beutels P; Boersma C; Postma MJ;
    J Infect Dis; 2022 Aug; 226(Suppl 1):S102-S109. PubMed ID: 34522947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.
    Zhang L; Durr E; Galli JD; Cosmi S; Cejas PJ; Luo B; Touch S; Parmet P; Fridman A; Espeseth AS; Bett AJ
    Vaccine; 2018 Dec; 36(52):8119-8130. PubMed ID: 30340881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
    Green CA; Sande CJ; Scarselli E; Capone S; Vitelli A; Nicosia A; Silva-Reyes L; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Hutchings CL; Cargill T; Angus B; Klenerman P; Pollard AJ
    J Infect; 2019 May; 78(5):382-392. PubMed ID: 30742894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults.
    Sadoff J; De Paepe E; Haazen W; Omoruyi E; Bastian AR; Comeaux C; Heijnen E; Strout C; Schuitemaker H; Callendret B
    J Infect Dis; 2021 Feb; 223(4):699-708. PubMed ID: 32851411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.
    Walsh EE; Pérez Marc G; Zareba AM; Falsey AR; Jiang Q; Patton M; Polack FP; Llapur C; Doreski PA; Ilangovan K; Rämet M; Fukushima Y; Hussen N; Bont LJ; Cardona J; DeHaan E; Castillo Villa G; Ingilizova M; Eiras D; Mikati T; Shah RN; Schneider K; Cooper D; Koury K; Lino MM; Anderson AS; Jansen KU; Swanson KA; Gurtman A; Gruber WC; Schmoele-Thoma B;
    N Engl J Med; 2023 Apr; 388(16):1465-1477. PubMed ID: 37018468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results from the WHO external quality assessment for the respiratory syncytial virus pilot, 2016-17.
    Jackson S; Peret TCT; Ziegler TT; Thornburg NJ; Besselaar T; Broor S; Barr I; Baumeister E; Chadha M; Chittaganpitch M; Darmaa B; Ellis J; Fasce R; Herring B; Herve K; Hirve S; Li Y; Pisareva M; Moen A; Naguib A; Palekar R; Potdar V; Siqueira M; Treurnicht F; Tivane A; Venter M; Wairagkar N; Zambon M; Zhang W
    Influenza Other Respir Viruses; 2020 Nov; 14(6):671-677. PubMed ID: 32730685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults.
    Falloon J; Yu J; Esser MT; Villafana T; Yu L; Dubovsky F; Takas T; Levin MJ; Falsey AR
    J Infect Dis; 2017 Dec; 216(11):1362-1370. PubMed ID: 29029260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory syncytial virus in adults with comorbidities: an update on epidemiology, vaccines, and treatments.
    Bouzid D; Visseaux B; Ferré VM; Peiffer-Smadja N; Le Hingrat Q; Loubet P
    Clin Microbiol Infect; 2023 Dec; 29(12):1538-1550. PubMed ID: 37666450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States.
    Herring WL; Zhang Y; Shinde V; Stoddard J; Talbird SE; Rosen B
    Vaccine; 2022 Jan; 40(3):483-493. PubMed ID: 34933763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.